not tagged
debio pharmaceuticals,merck
['headandneck', 'debiopharm', 'merck']
five-year data reported at #esmo22 shows that and ' iap antagonist #xevinapant almost doubles survival when compared to placebo in patients with #headandneckcancer 
https://t.co/O0ZJQGuINh, and its digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate